Literature DB >> 2064944

The relationship between plasma psoralen concentration and psoralen-UVA erythema.

J Mclelland1, C Fisher, P M Farr, B L Diffey, N H Cox.   

Abstract

The plasma 8-methoxypsoralen (8-MOP) concentration was measured in 60 patients commencing psoralen photochemotherapy (PUVA). At the time of blood sampling each patient was phototested using a series of 10 exposures to UVA. The resulting erythema was measured objectively 72 h after irradiation and dose-response curves for psoralen-UVA erythema were constructed. Although the dose of 8-MOP was calculated according to body weight, patients receiving 30 mg of 8-MOP had a significantly lower mean plasma concentration than those receiving higher doses. There was no significant correlation between plasma 8-MOP concentration and minimal phototoxic dose, either estimated visually or calculated from the dose-response curves. However the slope of the dose-response curve showed significant correlation with plasma 8-MOP concentration. The variation between patients in the rate of increase of the erythemal response, but not the variation in threshold sensitivity, can be explained by difference in plasma psoralen concentration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2064944     DOI: 10.1111/j.1365-2133.1991.tb04956.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  2 in total

1.  Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration.

Authors:  Marcella Grundmann-Kollmann; Maurizio Podda; Lutz Bräutigam; Katja Hardt-Weinelt; Ralf J Ludwig; Gerd Geisslinger; Roland Kaufmann; Irmgard Tegeder
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

2.  Cytochrome P450 CYP1B1 interacts with 8-methoxypsoralen (8-MOP) and influences psoralen-ultraviolet A (PUVA) sensitivity.

Authors:  Yusuf Y Deeni; Sally H Ibbotson; Julie A Woods; C Roland Wolf; Gillian Smith
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.